Consequently, the stabilization of p53 and activation of its tumor-suppressive functions through the inhibition of its interactions with E3 ligases—primarily MDM2—has become a pressing therapeutic goal [78,79,80]. This evidence concerns the gene MDM2 and neoplasm.